Cellid IPO To Fund First-In-Class Cancer Immunotherapeutic Vaccines
After using government financial support to fund its early-stage clinical trials, Korean bioventure Cellid aims to further progress its first-in-class, cell-based cancer immunotherapeutic vaccines through an initial public offering in February.
You may also be interested in...
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.
At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.
A recent forum in South Korea heard from a venture capital executive about the changing IPO and financing environment and how bioventures might be able to cope with these changes.